Status:
UNKNOWN
Multidisciplinary Bladder-preservation Therapy for Bladder Cancer
Lead Sponsor:
Peking University Third Hospital
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A multidisciplinary approach has led to the development of bladder-preservation therapy using maximal transurethral resection followed by radiotherapy with concomitant radio-sensitizing chemotherapy f...
Detailed Description
Multidisciplinary management improves complex treatment decision making in cancer care, but its impact for bladder cancer has not been documented. Although radical cystectomy (RC) has long been the st...
Eligibility Criteria
Inclusion
- Bladder urothelial carcinoma
- Clinical stage: T2-T4, non-metastasis
- Eastern Cooperative Oncology Group score (ECOG)≤ 1, Karnofsky performance score≥ 70
- Patients don't want to receive RC or are not candidates for RC
- Normal bladder function
Exclusion
- History of abdominal and pelvic radiotherapy
- History of other malignant tumor
- Pregnant or lactating patients
- Severe comorbidity: cardiac infarction, arrhythmia, heart failure, et al
Key Trial Info
Start Date :
November 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT03756207
Start Date
November 1 2018
End Date
December 31 2021
Last Update
November 28 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191